United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $2.41, $1.97 worse than the analyst estimate of $4.38. Revenue for the quarter came in at $466.9 million versus the consensus estimate of $460.67 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.